Please login to the form below

Not currently logged in
Email:
Password:

Oxford BioMedica

This page shows the latest Oxford BioMedica news and features for those working in and with pharma, biotech and healthcare.

Oxford Biomedica gets £53m cash injection from Novo venture arm

Oxford Biomedica gets £53m cash injection from Novo venture arm

Cell and gene therapy specialist Oxford Biomedica has been given a £53.5m infusion of cash from Novo Holdings in exchange for a 10% stake in the company. ... John Dawson. “We are delighted that Novo Holdings has become a shareholder in Oxford Biomedica

Latest news

More from news
Approximately 3 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    95. Oxford BioMedica/Novartis. Expansion of collaboration. Lentiviral vectors expressing CTL019 CAR-T therapy for leukaemia.

  • Pharma deals during October 2014 Pharma deals during October 2014

    First closed in May 2013, Novartis has expanded its collaboration with Oxford BioMedica. ... This is focused on the manufacture and supply, using Oxford's LentiVector gene delivery technology, to express Novartis' chimeric antigen receptor T cell [CAR-T]

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Pharma industry appointments Pharma industry appointments

    Prior to this, he was non-executive director and then chairman of Oxford BioMedica, a gene-based biopharmaceutical company.

  • Dr Simon Chandler joins Ora as a senior director Dr Simon Chandler joins Ora as a senior director

    Prior to joining Ora, Dr Chandler served as principal of Sci-pHecta Consulting from 2013 and has also held leadership roles at Bausch Lamb, Ista Pharmaceuticals, NightStaRx BioPharmaceuticals and Oxford BioMedica

  • ABPI names first project director for manufacturing ABPI names first project director for manufacturing

    James Christie joins from Oxford BioMedica. The Association of the British Pharmaceutical Industry (ABPI) has named James Christie as its first project director with responsibility for manufacturing. ... Prior to joining ABPI, Christie worked for Oxford

  • Paul Blake joins Oxford BioMedica Paul Blake joins Oxford BioMedica

    John Dawson, CEO of Oxford BioMedica, said: “His insight and guidance as a Non-Executive Board member have been invaluable and his extensive experience in the strategic clinical development of innovative ... therapies will be important to Oxford

  • BIA elects six new board members BIA elects six new board members

    The remaining new appointments are Stephen Taylor of Fujifilm Diosynth Biotechnologies; Donna Hackett, director of life sciences consultancy firm KDH BioManagement; and Tim Watts, chief financial officer of Oxford BioMedica.

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics